Intravaginal use of natural micronised progesterone to prevent pre-term birth: A randomised trial in India

References

• Cicinelli E, Schonauer L M, Galantino P, Matteo M G, Cassetta R, Pinto V. Mechanisms of uterine specificity of vaginal progesterone. Human Reproduction 2000; 15: 159–165
   PubMed Web of Science ®Google Scholar
• Creasy R K. Pre-term birth prevention: where are we?. American Journal of Obstetrics and Gynecology 1993; 168: 1223–1230
   PubMed Web of Science ®Google Scholar
• da Fonseca E B, Bittar R E, Carvalho M H, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous pre-term birth in women at increased risk: a randomized placebo-controlled double-blind study. American Journal of Obstetrics and Gynecology 2003; 188: 419–424
   PubMed Web of Science ®Google Scholar
• DeFranco E A, O'Brien J M, Adair C D, Lewis D F, Hall D R, Fusey, et al. Vaginal progesterone is associated with a decrease in risk for early pre-term birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics and Gynecology 2007; 30: 697–705
   PubMed Web of Science ®Google Scholar
• Dodd J M, Flenady V, Cincotta R, Crowther C A. Prenatal administration of progesterone for preventing pre-term birth. Cochrane Database Syst Rev 2006; 1: CD004947
   Google Scholar
• Fuchs A R, Fuchs F. Endocrinology of human parturition: a review. British Journal of Obstetrics and Gynaecology 1984; 91: 948–967
   PubMedGoogle Scholar
• Johnson J W, Austin K L, Jones G S, Davis G H, King T M. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine 1975; 293: 675–680
   PubMed Web of Science ®Google Scholar
• Keirse M J. Progestogen administration in pregnancy may prevent pre-term delivery. British Journal of Obstetrics and Gynaecology 1990; 97: 149–154
   PubMedGoogle Scholar
• Levy T, Gurevitch S, Bar-Hava I, Ashkenazi J, Magazanik A, Homburg R, et al. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. Human Reproduction 1999; 14: 606–610
   PubMed Web of Science ®Google Scholar
• Lockwood C J, Senyei A E, Dische M R, Casal D, Shah K D, Thung S N, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of pre-term delivery. New England Journal of Medicine 1991; 325: 669–674
   PubMed Web of Science ®Google Scholar
• Mackenzie R, Walker M, Armson A, Hannah M E. Progesterone for the prevention of pre-term birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. American Journal of Obstetrics and Gynecology 2006; 194: 1234–1242
   PubMed Web of Science ®Google Scholar
• Meis P J, Klebanoff M, Thom E, Dombrowski M P, Sibai B, Moawad A H, et al. Prevention of recurrent pre-term delivery by 17 alpha-hydroxyprogesterone caproate. New England Journal of Medicine 2003; 348: 2379–2385
   PubMed Web of Science ®Google Scholar
• Nugent R P, Krohn M A, Hillier S L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. Journal of Clinical Microbiology 1991; 29: 297–301
   PubMed Web of Science ®Google Scholar
• O'Brien J M, Adair C D, Lewis D F, Hall D R, Defranco E A, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent pre-term birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics and Gynecology 2007; 30: 687–696
   PubMed Web of Science ®Google Scholar
• Papiernick-Berkhauer E. Double blind study of an agent to prevent preterm delivery among women at increased risk. Schering, 1970; 65–68, Series 4
   Google Scholar
• Pschirrer E R, Monga M. Risk factors for pre-term labor. Clinical Obstetrics and Gynecology 2000; 43: 727–734
   PubMedGoogle Scholar
• Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of pre-term birth. International Journal of Gynaecology and Obstetrics 2009; 104: 40–43
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramos L, Kaunitz A M, Delke I. Progestational agents to prevent pre-term birth: a meta-analysis of randomized controlled trials. Obstetrics and Gynecology 2005; 105: 273–279
   PubMed Web of Science ®Google Scholar
• Spong C Y, Meis P J, Thom E A, Sibai B, Dombrowski M P, Moawad A H, et al. Progesterone for prevention of recurrent pre-term birth: impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology 2005; 193: 1127–1131
   PubMed Web of Science ®Google Scholar
• Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Human Reproduction Update 2000; 6: 139–148
   PubMed Web of Science ®Google Scholar
• Tognoni G, Ferrario L, Inzalaco M, Crosignani P G. Progestogens in threatened abortion. Lancet 1980; 2: 1242–1243
   PubMed Web of Science ®Google Scholar
• Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner B M, Kessler I, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology 1985; 151: 574–577
   PubMed Web of Science ®Google Scholar